title: [Efficacies of ¹³¹I-chTNT plus radiofrequency ablation for the treatment of advanced hepatocellular carcinoma].
abstract: OBJECTIVE
  To evaluate the efficacies of radiofrequency ablation (RFA) plus iodine (¹³¹I) tumor necrosis therapy monoclonal antibody (¹³¹I-chTNT) for advanced stage hepatocellular carcinoma.
  
  
  METHODS
  The clinical data of 38 hepatocellular carcinoma patients confirmed clinically or pathologically were retrospectively analyzed. They were divided into 2 groups (RFA group, n = 22; combination group, n = 16) according to the treatment mode. The median follow-up period was 31 (8-49) months.Survival was estimated with the Kaplan-Meier method and the survival curve compared by log-rank test.
  
  
  RESULTS
  Thirteen cases in RFA group and 7 cases in combination group died of tumor progression or complications of liver cirrhosis. The median survival time in combination group was significantly than RFA group (43 vs 37 months) (P = 0.039). The overall survival rates at 1, 2 and 3 years (100%, 87.5%, 75% respectively) were higher than those in RFA group (81.8%, 58.2%, 51.7% respectively).
  
  
  CONCLUSIONS
  For hepatocellular carcinoma with a special site and a diameter ≥ 5 cm, RFA plus ¹³¹I-chTNT treatment can prolong progression-free survival time. And its short-term curative effect is better than that of RFA therapy. And the long-term outcomes may be further explored by a large-sample, multi-center and randomized trial.
authors.affiliation: Department of Radiology and Interventional Radiology, Central Municipal Hospital, Lishui 323000, China.
authors.forename: Jianfei
authors.initials: J
authors.lastname: Tu
authors.affiliation: Department of Radiology and Interventional Radiology, Central Municipal Hospital, Lishui 323000, China. Email: jjstcty@sian.com.
authors.forename: Jiansong
authors.initials: J
authors.lastname: Ji
authors.affiliation: Department of Radiology and Interventional Radiology, Central Municipal Hospital, Lishui 323000, China.
authors.forename: Fazong
authors.initials: F
authors.lastname: Wu
authors.affiliation: Department of Radiology and Interventional Radiology, Central Municipal Hospital, Lishui 323000, China.
authors.forename: Dengke
authors.initials: D
authors.lastname: Zhang
authors.affiliation: Department of Radiology and Interventional Radiology, Central Municipal Hospital, Lishui 323000, China.
authors.forename: Xihui
authors.initials: X
authors.lastname: Ying
authors.affiliation: Department of Radiology and Interventional Radiology, Central Municipal Hospital, Lishui 323000, China.
authors.forename: Zhongwei
authors.initials: Z
authors.lastname: Zhao
mesh_terms: D000911:Antibodies, Monoclonal; D006528:Carcinoma, Hepatocellular; D017115:Catheter Ablation; D018572:Disease-Free Survival; D006801:Humans; D007457:Iodine Radioisotopes; D008113:Liver Neoplasms; D012189:Retrospective Studies
chemical_list: D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes